Figures
Abstract
Interferon (IFN) inhibits hepatitis C virus (HCV) replication through up-regulation of intrahepatic IFN-stimulated gene expression but also through activation of host immune cells. In the present study, we analyzed the immune cell-mediated antiviral effects of IFN-α using HCV-infected mice. Urokinase-type plasminogen activator (uPA)-severe combined immunodeficiency (SCID) mice with transplanted human hepatocytes were infected with genotype 1b HCV and injected with human peripheral blood mononuclear cells (PBMCs). IFN-α treatment following human PBMC transplantation resulted in a significant reduction in serum HCV RNA titers and a higher human CD45-positive mononuclear cell chimerism compared to mice without human PBMC transplantation. In mice with human PBMCs treated with IFN-α, serum concentrations of IFN-γ increased, and natural killer T (NKT) cells, especially type I NKT cells, produced IFN-γ. Mice in which IFN-γ signaling was blocked using antibody or in which transplanted PBMCs were depleted for type I NKT cells showed similar levels of anti-HCV effect compared with mice treated only with IFN-α. These results show that IFN-α stimulates IFN-γ expression in type 1 NKT cells and enhances the inhibition of HCV replication. We propose that type 1 NKT cells might represent a new therapeutic target for chronic hepatitis C patients.
Citation: Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, et al. (2017) Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS ONE 12(3): e0172412. https://doi.org/10.1371/journal.pone.0172412
Editor: Ranjit Ray, Saint Louis University, UNITED STATES
Received: September 28, 2016; Accepted: February 3, 2017; Published: March 2, 2017
Copyright: © 2017 Miyaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This research is supported by research funding from the Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED (grant number: 15fk0210001h0002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study. PhoenixBio Co. Ltd. provided support in the form of salaries for authors YI and CT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Competing interests: We have the following interests. Kazuaki Chayama received honoraria from MSD K.K., Bristol-Meyers Squibb, Gilead Sciences and AbbVie and research funding from Dainippon Sumitomo Pharma, TORAY, Eisai, Otsuka Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo and Bristol-Meyers Squibb. Michio Imamura received honoraria and research funding from Bristol-Meyers Squibb. Masataka Tsuge received research funding from Bristol-Meyers Squibb. Yuji Ishida and Chise Tateno are employed by PhoenixBio Co. Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Abbreviations: ALT, alanine aminotransferase; DAA, direct acting antiviral; GBP, GTP-binding protein; HCV, hepatitis C virus; HSA, human serum albumin; IFN, interferon; ISGs, interferon-stimulated genes; NK, natural killer; PBMCs, peripheral blood mononuclear cells; uPA, urokinase-type plasminogen activator; SCID, severe combined immunodeficiency; SVR, sustained virological response; RAVs, resistance-associated variants
Introduction
Approximately 170 million people worldwide are chronically infected with hepatitis C virus (HCV) [1]. As a major risk factor for cirrhosis and hepatocellular carcinoma (HCC), HCV infection is one of the leading causes of cancer-related deaths [2]. The current therapy for HCV is the combination of two or more direct-acting antivirals (DAAs) without interferon (IFN) [3, 4]. Although these therapies are able to achieve a high sustained virological response (SVR) rate, there are a few patients who nonetheless fail to respond to the treatment. The most important factor is the existence of resistance-associated variants (RAVs) to one or more of the DAAs. IFN is a treatment option for chronic hepatitis C patients with DAA RAVs.
IFN eliminates HCV through both direct and indirect effects on hepatocytes [5]. IFN directly binds to HCV-infected hepatocyte surface receptors and inhibits HCV replication by inducing the expression of IFN-stimulated genes (ISGs) [6]. Indirectly, IFN activates host immune cells, such as natural killer (NK) cells and T cells [7], and these activated immune cells exhibit antiviral activity by producing cytokines. NK cells were reported to produce cytokines and suppress HCV replication following activation by IFN [8–13]. T cells have also been reported to suppress HCV activity after stimulation by IFN [7, 14–16].
Natural killer T (NKT) cells are a unique subset of lymphocytes that co-express T-cell receptors and NK cell markers [17]. NKT cell activation was reported to be correlated with subsequent T cell response [18], resulting in depletion of chronic intrahepatic NKT cell populations and reduction of HCV infection [19]. However, little is known about the role of NKT cells in HCV infection.
We previously reported an animal model of HCV-infected human hepatocyte transplanted chimeric mice by transplanting human liver lymphocytes using urokinase-type plasminogen activator-severe combined immunodeficiency (uPA-SCID) mice [20]. In this study, we investigated the IFN-induced immune response using the same mouse model with HCV-infection and human immunity by transplanting human peripheral mononuclear cells (PBMCs).
Materials and methods
Generation of human hepatocyte chimeric mice
Generation of the uPA+/+/SCID+/+ mice and transplantation of human hepatocytes with HLA-A24 were performed as described previously [21]. All mice were transplanted with frozen human hepatocytes obtained from the same donor. Mouse serum concentrations of human serum albumin (HSA), which is correlated with the liver repopulation index, were measured as described previously [21]. All animal protocols described in this study were performed in accordance with the Guide for the Care and Use of Laboratory Animals and the local committee for animal experiments, and the experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of the Graduate School of Biomedical Sciences, Hiroshima University.
Human serum samples
Human serum samples containing high titers of genotype 1b HCV RNA (2.2 x 106 copies/mL) were obtained from patients with chronic hepatitis who provided written informed consent. Individual serum samples were divided into aliquots and stored in liquid nitrogen. Six weeks after hepatocyte transplantation, chimeric mice were injected intravenously with 50 μL of HCV-positive human serum.
Preparation of human PBMCs and transplantation into human hepatocyte chimeric mice
PBMCs were isolated using Ficoll-Hypaque density gradient centrifugation from a healthy blood donor with HLA-A24. Eight to ten weeks after HCV inoculation, 4×107 human PBMCs were transplanted into human hepatocyte chimeric mice. To assess the effect of depletion of human type I NKT cells from administered PBMCs on hepatitis formation, Anti-iNKT Micro Beads (Milteny Biotec, CA, USA) were used.
Quantitation of HCV RNA and ISG mRNAs
RNA was extracted from mouse serum and liver samples by SepaGene RV-R (EIDIA Co.,LTD., Tokyo, Japan), and dissolved in 8.8 μL RNase-free water. Extracted RNA was reverse transcribed using random primer (Takara Bio Inc., Shiga, Japan) and M-MLV reverse transcriptase (ReverTra Ace, TOYOBO Co.,LTD., Osaka, Japan) in 20 μL reaction mixture according to the instructions provided by the manufacturer. Nested polymerase chain reaction (PCR) and HCV quantitation by Light Cycler (Roche Diagnostics K.K., Tokyo, Japan) were performed as previously described [22]. Quantitation of ISG expression (HLA-DMB, GTP-binding protein [GBP5]) was performed using real-time PCR Master Mix (TOYOBO) and TaqMan Gene Expression Assay primer and probe sets (PE Applied Biosystems, Foster City, CA). Thermal cycling conditions were as follows: a precycling period of 1 min at 95°C followed by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min. Expression levels of each ISG are expressed as a ratio with respect to β-actin levels.
Treatment of mice with IFN and anti-IFN-γ antibody
To analyze the immune response to IFN, mice received daily intramuscular injections of either 1000 IU/g of human IFN-α (Dainippon Sumitomo Pharma Co., Tokyo, Japan) or human IFN-γ (Shionogi & Co., Ltd, Osaka, Japan) for 7 days after human PBMC transplantation. To analyze the antiviral effect of IFN-γ, mice received intraperitoneal injections with either 1.5 mg of anti-human IFN-γ antibody or isotype antibody (R&D Systems, Minneapolis, MN) one day before human PBMC transplantation. Anti-human IFN-gamma antibody has no cross-reactivity with mouse IFN-gamma, and blocks human IFN-gamma specifically.
Flow cytometry
We collected mouse liver infiltrating cells flowing through the portal vein after hepatectomy [23]. Reconstructed human PBMCs in mice were analyzed by flow cytometry with the following mAbs used for surface and intracellular staining: APC-H7 Anti-Human cluster of differentiation (CD)3 (clone SK7), APC conjugated anti-CD4 (clone SK), BD Horizon™ V450 Anti-Human CD8 (clone RPA-T8), HU HRZN V500 MAB conjugated anti-Human CD45 (clone H130), Alexa Fluor 488 conjugated anti-Human CD56 (clone B159), PE conjugated anti-Human CD25 (clone M-A251), and PE-Cy7-conjugated anti-Mouse CD45 (clone 30-F11). Each of the above mAbs was purchased from BD Bioscience. PE-conjugated IFN-γ (clone 45.15), FITC-conjugated TCRα24 (clone C15) and APC-conjugated TCRβ11 (clone C21) were purchased from Beckman Coulter Co., (Tokyo, Japan). Dead cells identified by light scatter and propidium iodide staining were excluded from the analysis. For intracellular staining, cells were permeabilized and fixed after surface staining using the BD Cytofix/Cytoperm kit (BD Bioscience, Heidelberg, Germany). Flow cytometry was performed using a FACSAria™ II flow cytometer (BD Bioscience), and results were analyzed with FlowJo (TreeStar). NKT cells were defined as human CD3+CD56+ cells, and type I NKT cells were defined as Vα24+ and Vβ11+ cells.
Histochemical analysis of mouse liver
Histochemical analysis and immunohistochemical staining using antibodies against HSA (Bethyl Laboratories Inc., Montgomery, TX) were performed as described previously [24–26]. Immunoreactive materials were visualized using a streptavidin-biotin staining kit (Histofine SABPO kit; Nichirei, Tokyo, Japan) and diainobenzidine.
Cytokine assay
The concentrations of human IFN-γ, granzyme A, granzyme B, interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A and mouse IFN-γ were quantified by chemokine cytometric bead array (CBA) kits (BD Biosciences, Heidelberg, Germany) in accordance with the manufacturer’s instructions. The minimum and maximum detection limits were 10 and 2500 pg/mL, respectively. Mouse serum cytokine levels were measured before and 4 and 7 days after IFN-α injection.
Results
Human PBMCs enhanced the antiviral effects of IFN-α in HCV-infected human hepatocyte chimeric mice
HCV-infected human hepatocyte chimeric mice were treated with 4×107 human PBMCs obtained from a healthy volunteer. PBMC treatment showed a slight reduction in mouse serum HCV RNA levels (Fig 1A). Seven days of human IFN-α treatment without human PBMC injection in mice reduced serum HCV RNA levels by 1.23 ± 0.15 log, whereas in combination with PBMCs, HCV RNA levels were reduced by 2.5 ± 0.45 log (P<0.01). Mouse serum HSA levels did not decrease during these treatments. Histological examination showed that neither human PBMC injection nor treatment with IFN-α resulted in apparent damage to human hepatocytes at seven days after treatment (Fig 1B). Serum human ALT levels in mouse serum also showed no increase in PBMC- or IFN-α-treated mice (S1 Fig). Therefore, the reduction of HCV in mice with PBMC injection and IFN-α treatment was concluded not to be due to toxicity of these treatments.
HCV-infected human hepatocyte chimeric mice were injected with or without 4×107 human PBMCs, and then treated with or without 1000 IU/kg of IFN-α for seven days. (a) Time course of HCV RNA titer (upper panel) and human albumin (lower panel) in mouse serum. Data are presented as the mean ± SD. Mice without HCV infection were also shown. (b) Histological analysis of liver samples obtained from mice. Liver samples at seven days after injection of human PBMCs were stained with hematoxylin-eosin staining (HE) and immunohistostained with anti-HSA antibody (human albumin). Most cells in the regions shown are human hepatocytes (original magnification, ×40).
Analysis of liver-infiltrating human lymphocytes in mice
We analyzed liver-infiltrating cells for human cell surface markers in mice injected with human PBMCs. Flow cytometry analysis showed that treatment with 7 days of IFN-α resulted in significantly greater human CD45-positive mononuclear cell chimerism in HCV-infected mice compared to mice without IFN-α treatment (21.2 ± 8.5% and 5.8 ± 0.8%, respectively; P<0.01) (Fig 2A). In IFN-α-treated mouse livers, the frequencies of NK, NKT and T cells were not changed, indicating that the numbers of each of these cells increased following IFN-α treatment (Fig 2B).
HCV-infected human hepatocyte chimeric mice were injected with 4×107 human PBMCs, then treated with (n = 6) or without (n = 4) 1000 IU/kg of IFN-α for seven days. Liver mononuclear cells were isolated from mice seven days after human PBMC treatment. (a) Liver mononuclear cells were stained with antibodies against human CD45 and mouse CD45, and analyzed by flow cytometry (upper panel). Statistical analysis of differences in the percentage of human mononuclear cells in PBMCs-treated mice with or without IFN-α is shown in the lower panel. Data are presented as the mean ± SD. (b) Liver mononuclear cells were stained with antibodies against human CD3 and human CD56 and analyzed by flow cytometry (upper panel). Percentages of human mononuclear cells in PBMCs-treated mice are shown in the lower panel. Data are presented as the mean ± SD.
IFN-γ is essential for antiviral effect in mice treated with human PBMCs and IFN-α
The cytokine time course assay demonstrated that mouse serum human IFN-γ increased four days after human PBMC injection and IFN-α treatment (Fig 3A). No up-regulation of human IFN-γ was observed in either PBMC- nor IFN-α-treated mice. Other cytokines such as TNF-α (Th1), IL-2 (Th1), IL-4 (Th2), IL-17 (Th17) were undetectable. Flow cytometry analysis showed that NKT cells, especially type I NKT cells, produced IFN-γ at seven days after treatment (Fig 3B). Although the populations of type I NKT cells did not increase, the number of IFN-γ producing type I NKT cells increased dramatically following IFN-α treatment (S2 Fig). These IFN-γ-producing type I NKT cells were more abundant compared to T cells or NK cells (S3 Fig). Along with up-regulation of IFN-γ, the expression of intrahepatic IFN-γ-specific ISGs such as HLA-DMB and GBP5 had increased in human PBMC- and IFN-α-treated mice 24 hrs after IFN-α injection (Fig 3C), suggesting that these ISGs contribute to serum HCV RNA reduction following IFN-α treatment.
Mice were treated as described in the legend to Fig 2. (a) Time course of serum IFN-γ concentration in mice treated with or without IFN-α. Mice treated with IFN-α without PBMC injection were also analyzed. Data are presented as the mean ± SD. (b) Liver mononuclear cells were stained with antibodies against human CD3 and CD56, human TCR Vα24, and TCR Vβ11 and analyzed by flow cytometry (upper panel). The frequency of IFN-γ-positive cells in NKT cells, and type I NKT cells were analyzed (lower panel). (c) Twenty-four hrs after IFN-α injection, intrahepatic gene expression levels of HLA-DMB and GTP-binding protein 5 (GBP5) were measured. RNA levels are expressed relative to β-actin mRNA. Data are represented as the mean ± SD of 3 mice.
To assess the role of IFN-γ in HCV inhibition, a blocking monoclonal antibody (mAb) against human IFN-γ was administered to mice before addition of human PBMCs and IFN-α treatment. Treatment of mice with anti-IFN-γ antibody before IFN-α treatment eliminated the antiviral effect of human PBMCs and IFN-α (Fig 4A). Development of human CD45-positive mononuclear cell chimerism by treatment with human PBMCs and IFN-α treatment was also completely negated by anti-IFN-γ antibody (Fig 4B), suggesting that IFN-γ produced by NKT cells is essential not only for its direct antiviral effect, but also for the development of human lymphocyte chimerism in mice treated with human PBMCs and IFN-α.
HCV-infected human hepatocyte chimeric mice were injected with 4×107 human PBMCs. The mice were then treated with 1000 IU/kg of IFN-α for 7 days. One day before human PBMC transplantation, mice were injected either with isotype (n = 3) or with antibody against IFN-γ (n = 3). (a) Reductions of serum HCV RNA levels and human albumin concentrations are shown. Mice treated with IFN without PBMCs injection were also analyzed (gray circles). Data are presented as the mean ± SD. (b) Liver mononuclear cells isolated from mice were stained with antibodies against human CD45 and mouse CD45, and analyzed by flow cytometry (upper panel). Statistical analysis of the frequencies of human mononuclear cells in PBMC-treated mice are shown in the lower panel. Data are presented as the mean ± SD.
Effect of Type I NKT cell depletion on antiviral effect
To confirm the necessity of type I NKT cells for antiviral effect, we depleted type I NKT cells with negative selection using antibody-coated magnetic beads before administration of PBMCs. Serum HCV RNA levels in mice treated with type I NKT-depleted PBMCs and IFN-α decreased to levels similar to that of mice treated only with IFN-α (Fig 5A). Development of human CD45-positive mononuclear cell chimerism was also prevented in mice administered with type I NKT-depleted PBMCs and IFN-α, and the chimerism decreased to the same level as in mice without IFN-α treatment (Fig 5B).
HCV-infected human hepatocyte chimeric mice were injected with whole human PBMCs or type 1 NKT-depleted human PBMCs (n = 3), and then treated with (n = 6) or without (n = 4) 1000 IU/kg of IFN-α for seven days. (a) Reduction of serum HCV RNA levels (upper panel) and human albumin concentrations (lower panel) are shown. IFN-α treated mice without human PBMC transplantation were also analyzed. Data are presented as the mean ± SD. (b) Liver mononuclear cells isolated from mice seven days after human PBMC treatment were stained with antibodies against human CD45 and mouse CD45, and analyzed by flow cytometry (upper panel). Statistical analysis of the frequencies of human mononuclear cells in PBMCs-treated mice is shown in the lower panel. Data are presented as the mean ± SD.
Discussion
NKT cells are thought to serve as a bridge between innate immune cells, including NK cells and dendritic cells, and acquired immune effectors, consisting of T cells [27]. The network of activation initiated by NKT cells extends to activation of B cells and T cells. We previously reported that although human PBMCs in human hepatocyte chimeric mice were detected during the first week, those cells were almost undetectable by day 14 because of the activity of mouse NK cells and macrophages [24]. It was also thought that IFN-induced acute graft-versus-host disease occurred about twenty days after the transplantation [28]. Therefore, we analyzed the antiviral effect at seven days after the injection of human PMBCs.
In the present study, mice serum HCV RNA levels decreased by approximately 3 log IU/mL after PBMC transplantation and treatment with human IFN-α for seven days. In patients with chronic hepatitis C, one week of daily IFN-α treatment decreased serum HCV RNA levels by 2–3 log IU/mL [29]. Viral kinetics following IFN-α treatment in our mouse model appears to be similar with that of chronic hepatitis C patients. The reduction of serum HCV RNA levels in PBMC-transplanted mice treated with IFN-α was significantly higher than in mice without PBMC transplantation (Fig 1A). Based on the lack of increase in ALT levels (S1 Fig), unchanged human albumin levels (Fig 1A) and no apparent change in liver histology (Fig 1B), it was concluded that no liver damage was inflicted by treatment with human PBMCs and IFN. Based on our results, we hypothesized that an indirect effect of IFN in our mouse model was to enhance antiviral activity without damaging human hepatocytes. First, we analyzed the liver infiltrating human lymphocytes with flow cytometry. Surprisingly, there was a significantly higher human CD45-positive mononuclear cell chimerism in PBMC-transplanted mice that were treated with 1000 IU/g of IFN-α than in other mice (Fig 2A). Second, we examined the time course of serum concentrations of several cytokines in mouse serum. Although the concentration of cytokines was below the detection limit in most mice, administration of IFN-α significantly increased serum concentration of human IFN-γ four days after PBMC injection (Fig 3A). Third, we analyzed the infiltration of mononuclear cells in mouse liver with flow cytometry to identify IFN-producing cells, including NK cells, T cells and NKT cells [30]. We detected IFN-γ-positive cells among the NKT cells. NKT cells are divided into type I and type II subsets [31]. Type I NKT cells are pro-inflammatory and secrete IFN-γ and are defined by a restricted T-cell receptor repertoire, which in humans consists of the T-cell receptor (TCR) chains Vα24-Ja18 and Vβ11 with a conserved CDR3 [32]. In this study, the majority of type I NKT cells of HCV-infected mice treated with IFN-α was IFN-γ-positive (Fig 3B). IFN-γ-specific ISGs [33] were significantly more strongly up-regulated in PBMC-transplanted chimeric mice treated with IFN-α than in mice without human PBMCs (Fig 3C).
We performed several experiments to assess the importance of IFN-γ and verify the presence of NKT cells. The inhibition of IFN-γ by anti-IFN-γ antibody dramatically reduced the antiviral effect (Fig 4A) and significantly decreased human CD45-positive cell chimerism in HCV-infected mice (Fig 4B). Although levels of human IFN-γ in mouse serum increased following administration of human PBMCs and IFN-α, mice IFN-γ levels were below the detectable limit (data not shown). These results showed that the effect of IFN-γ antibody was due to the inhibition of human IFN-γ produced from human PBMCs, and IFN-γ was crucial to the immune response. The antiviral effect of HCV-infected mice injected with type I NKT cell-depleted PBMCs was similar to the effect in HCV-infected mice treated only with IFN-α (Fig 5A), and human CD45-positive cell chimerism was similar to that in HCV-infected mice without IFN-α (Fig 5B).
To determine the antiviral effect of exogenous IFN-γ, we administered human IFN-γ to HCV-infected mice daily for one week (S4 Fig). In contrast to IFN-α, IFN-γ treatment showed no antiviral effect, indicating that local IFN-γ secreted from NKT cells in the livers seems to play an important role in antiviral activity in this mouse model.
NKT cells usually account for between 0.001–3% of human peripheral blood mononuclear cells [34]. In this study, the proportion of NKT cells was around 1% of human CD45-positive cells (Fig 2B). Despite this low frequency, depletion of human type I NKT cells from administered PBMCs decreased the anti-viral effect of IFN-α, indicating that type I NKT cells seem to play an important role on IFN-α-induced anti-HCV activity.
In summary, we analyzed immune cells present after treatment with IFN-α in HCV-infected human hepatocyte chimeric mice transplanted with human PBMCs. The IFN-γ secreted from NKT cells activated other immune cells and increased the antiviral effect. NKT cell-targeted adjuvant cell therapies were initially developed in clinical trials on cancer patients [27]. These NKT cells-targeted adjuvant cell therapies could be a new treatment option for refractory chronic hepatitis C.
Supporting information
S1 Fig. Changes in human alanine aminotransferase (ALT) levels in mouse serum.
HCV-infected human hepatocyte chimeric mice were injected with 4×107 human PBMCs, and then treated with or without 1000 IU/kg of IFN-α for seven days. Changes in human ALT levels in mouse serum are shown. Mice treated with PBMCs and IFN-α without HCV infection were also analyzed. Data are presented as the mean ± SD of 3 mice.
https://doi.org/10.1371/journal.pone.0172412.s001
(TIF)
S2 Fig. Analysis of the frequency of IFN-γ-positive cells in type I NKT.
HCV-infected human hepatocyte chimeric mice were injected with 4×107 human PBMCs, and then treated with (n = 6) or without (n = 4) 1000 IU/kg of IFN-α for seven days. Liver mononuclear cells were stained with antibodies against human TCR Vα24, and TCR Vβ11, and analyzed by flow cytometry. The frequency of type I NKT cells and IFN-γ-positive cells in type I NKT in PBMCs-injected mice are shown. Data are presented as the mean ± SD.
https://doi.org/10.1371/journal.pone.0172412.s002
(TIF)
S3 Fig. The frequency of IFN-γ-positive cells in T and NK cells.
HCV-infected human hepatocyte chimeric mice were injected with 4×107 human PBMCs, and then treated with 1000 IU/kg of IFN-α for seven days. Liver mononuclear cells were isolated from mice seven days after human PBMCs treatment. Liver mononuclear cells were stained with antibodies against human CD3 and CD56 and analyzed by flow cytometry. The frequency of IFN-γ-positive cells in T and NK cells were analyzed.
https://doi.org/10.1371/journal.pone.0172412.s003
(TIF)
S4 Fig. Treatment with IFN in HCV-infected human hepatocyte chimeric mice.
HCV-infected human hepatocyte chimeric mice were injected with or without 4×107 human PBMCs, and then treated with either 1000 IU/kg of FN-α or 20000 IU/kg of IFN-γfor 7 days. Reductions of serum HCV RNA levels and human albumin concentrations are shown. Data are presented as the mean ± SD.
https://doi.org/10.1371/journal.pone.0172412.s004
(TIF)
Acknowledgments
The authors thank Rie Akiyama and Yoko Matsumoto for their expert technical assistance and Akemi Sada and Emi Nishio for clerical assistance. Part of this work was carried out at the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University.
Author Contributions
- Conceptualization: KC.
- Data curation: MI HAC GNM KC.
- Formal analysis: EM NH H. Ochi.
- Funding acquisition: KC.
- Investigation: EM NH TU HK.
- Methodology: NH MI KC.
- Project administration: HA KC.
- Resources: MT HAC YI CT.
- Supervision: NH MI HA H. Ohdan KC.
- Visualization: NH MI MS.
- Writing – original draft: EM MI CNH KC.
References
- 1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16. pmid:10895428
- 2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. pmid:17570226
- 3. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8(5):471–9. PubMed Central PMCID: PMC4164256. pmid:25228970
- 4. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2015.
- 5. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–72. pmid:16107837
- 6. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology. 2006;43(5):961–72. pmid:16628626
- 7. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity. 2014;40(1):13–24. PubMed Central PMCID: PMC4480226. pmid:24439265
- 8. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195(3):343–51. PubMed Central PMCID: PMC2193591. pmid:11828009
- 9. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195(3):327–33. PubMed Central PMCID: PMC2193595. pmid:11828007
- 10. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology. 2010;138(4):1536–45. PubMed Central PMCID: PMC4183834. pmid:20080094
- 11. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141(4):1231–9, 9 e1-2. PubMed Central PMCID: PMC3353552. pmid:21741920
- 12. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology. 2012;55(1):39–48. PubMed Central PMCID: PMC3353526. pmid:21898483
- 13. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009;137(3):1151–60, 60 e1-7. pmid:19470388
- 14. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut. 2012;61(8):1226–34. pmid:21873736
- 15. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008;48(6):1753–60. pmid:18925643
- 16. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578–82. pmid:10802716
- 17. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21(11):573–83. pmid:11094262
- 18. Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology. 2013;58(5):1621–31. PubMed Central PMCID: PMC3688637. pmid:23463364
- 19. Deignan T, Curry MP, Doherty DG, Golden-Mason L, Volkov Y, Norris S, et al. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol. 2002;37(1):101–8. pmid:12076868
- 20. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest. 2009;119(11):3226–35. PubMed Central PMCID: PMCPMC2769186. pmid:19805910
- 21. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004;165(3):901–12. PubMed Central PMCID: PMC1618591. pmid:15331414
- 22. Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology. 2011;54(3):781–8. pmid:21626527
- 23. Ohdan H, Mizunuma K, Tashiro H, Tokita D, Hara H, Onoe T, et al. Intraoperative near-infrared spectroscopy for evaluating hepatic venous outflow in living-donor right lobe liver. Transplantation. 2003;76(5):791–7. pmid:14501855
- 24. Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, et al. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology. 2012;56(2):555–66. pmid:22331638
- 25. Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, et al. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem Biophys Res Commun. 2013;441(1):230–5. pmid:24140055
- 26. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005;42(5):1046–54. pmid:16250045
- 27. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol. 2010;22(1):1–6. pmid:19858073
- 28. Reyes VE, Klimpel GR. Interferon alpha/beta synthesis during acute graft-versus-host disease. Transplantation. 1987;43(3):412–6. pmid:3547798
- 29. Rossini A, Artini M, Levrero M, Almerighi C, Massari M, Biasi L, et al. Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. Dig Dis Sci. 2001;46(11):2389–95. pmid:11713941
- 30. Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol. 1999;163(4):2314–21. pmid:10438977
- 31. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004;4(3):231–7. pmid:15039760
- 32. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med. 1994;180(3):1097–106. PubMed Central PMCID: PMC2191643. pmid:7520467
- 33. Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, et al. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology. 2012;143(3):777–86 e1-6.
- 34. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11(2):131–42. pmid:21267014